Mission Biocapital β 2025 Investments
4 investments dated 2025 Β· listed companies and verified rows first Β· show all
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)Cam Gallagher(Executive Officer, Director)inJohn Maroney(Executive Officer, Director)
BoardZachary Collins(Executive Officer)inAnnie Mitsak(Director)in
Board seatDouglas CrawfordSteve TregayΒ· per SEC Form D
Co-investorsCure VenturesMission Bay Capital
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Board seatCassidy BlundellΒ· per SEC Form D
Co-investorsLongwood FundNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLCSofinnova Partners+2 more
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Board seatJohannes FruehaufΒ· per SEC Form D
Co-investorsDroia VenturesMC Healthcare VenturesMitsui Global InvestmentSanofi VenturesSV Health InvestorsAmgen Ventures+6 more
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMRL Ventures FundNextech InvestInkefRA Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.